Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 20/20 | 0.82 |
| ▸ | KDR | P35968 | 5/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.82 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.82 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.82 |
| ▸ | BTK | Q06187 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571308 | 1.00 | FGFR2 (0.82) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345761 | 0.93 | FGFR2 (0.84) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345762 | 0.93 | FGFR2 (0.84) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345429 | 0.91 | FGFR2 (0.84) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345432 | 0.91 | FGFR2 (0.84) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345392 | 0.90 | FGFR2 (1.00) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345504 | 0.90 | FGFR2 (0.83) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345507 | 0.90 | FGFR2 (0.83) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15345524 | 0.89 | FGFR2 (1.00) | FGFR2KDRFGFR1FGFR4FGFR3 | |
| SCHEMBL15137950 | 0.89 | FGFR2 (1.00) | FGFR2KDRFGFR1FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883404-B2 | Preparation and composition for treatment of malignant tumors | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2024-01-30 | — | — | US | disclosed |
| US-20190350932-A1 | PREPARATION AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883404-B2 | Preparation and composition for treatment of malignant tumors | FGFR3, FGFR1, FGFR4 | FGFR2 4/4885KDR 40/4885FGFR1 2/4885 |
| US-20190350932-A1 | PREPARATION AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | FGFR3, FGFR1, FGFR4 | FGFR2 4/4885KDR 40/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.